Marvelon

How to order Marvelon

1. Find the drug you need on our site.
2. Pick a clinic. See the price.
3. Fill in a short health form.
4. A doctor reads your form.
5. If it is safe for you, they say yes.
6. Your order ships fast to your door.
7. It comes in a plain, sealed box.

Why use us? We compare UK clinics. We show you the price and how fast they ship. We do not sell drugs. We just help you find the best one for you.

Is it safe? Yes. All our clinics are UK-based. A real doctor reads each form. They will not sell to you if it is not safe for you.

Marvelon on Prescriptsy

Marvelon is described on Prescriptsy as independent product information.

Here you can understand how online consultation works, what medical checks partner clinics carry out, and which factors matter when comparing providers.

We do not sell medicines directly, but help users compare licensed healthcare partners on price, delivery speed, service quality, and overall trustworthiness.

Marvelon is a combined oral contraceptive pill (COC) used to prevent pregnancy.

Each tablet contains two active ingredients: desogestrel 150 micrograms (a progestogen) and ethinylestradiol 30 micrograms (a synthetic oestrogen).

Marvelon is one of the most widely prescribed combined pills in the United Kingdom and has been available since 1981.

It is taken once daily for 21 days, followed by a 7-day tablet-free interval during which a withdrawal bleed typically occurs.

Marvelon is a prescription-only medicine (POM) and is available free of charge through the NHS, GP surgeries, and sexual health clinics.

Effective contraception is a cornerstone of reproductive healthcare.

Around 3.1 million women in the UK currently use hormonal contraception, with the combined pill remaining one of the most popular methods.

Choosing the right contraceptive involves balancing effectiveness, convenience, side effects, and individual risk factors.

This page provides a comprehensive clinical overview of Marvelon, including how it works, dosage guidance, side effects, important safety warnings, and how to obtain a prescription in the United Kingdom.

Important safety information about Marvelon

Before reading further, please note these essential safety points.

• Marvelon is a prescription-only medicine and should be used under medical supervision.
• All combined oral contraceptives carry a small increased risk of blood clots (venous thromboembolism). The risk with desogestrel-containing pills is slightly higher than with levonorgestrel-containing pills.
• Do not take Marvelon if you experience migraine with aura, as this significantly increases the risk of stroke.
• Smoking while taking the pill increases cardiovascular risk. Women over 35 who smoke must not use combined oral contraceptives.
• Marvelon does not protect against sexually transmitted infections. Use condoms for STI protection.

Understanding combined oral contraception

Combined oral contraceptives contain two types of hormone: an oestrogen and a progestogen.

The oestrogen component in Marvelon is ethinylestradiol, a synthetic oestrogen that has been the standard in COCs for decades.

The progestogen component is desogestrel, classified as a third-generation progestogen.

Third-generation progestogens were developed to offer better tolerability and fewer androgenic side effects (such as acne and unwanted hair growth) compared with second-generation progestogens like levonorgestrel.

Marvelon is a monophasic pill, meaning every active tablet in the pack contains the same dose of both hormones, which simplifies use and allows flexibility in adjusting the regimen.

The concept of generations of progestogens is relevant to understanding the risk profile of different pills. First-generation progestogens (norethisterone) are rarely used in modern COCs.

Second-generation progestogens (levonorgestrel) are associated with the lowest VTE risk among COCs and are recommended by NICE and the FSRH as first-line options when VTE risk is a primary concern.

Third-generation progestogens (desogestrel, gestodene) carry a slightly higher VTE risk but are sometimes preferred for women who experience androgenic side effects on second-generation pills.

How Marvelon works: mechanism of action

Marvelon prevents pregnancy through three complementary mechanisms. The primary mechanism is the suppression of ovulation.

The ethinylestradiol and desogestrel in Marvelon inhibit the release of gonadotrophins (follicle-stimulating hormone and luteinising hormone) from the anterior pituitary gland, preventing the mid-cycle LH surge that triggers ovulation.

Without ovulation, no egg is released for fertilisation.

The second mechanism involves changes to the cervical mucus.

Desogestrel causes the cervical mucus to become thicker and more viscous, creating a physical barrier that impedes sperm transport through the cervix into the uterus.

This effect is maintained throughout the pill-taking cycle and provides additional protection even if ovulation is not fully suppressed.

The third mechanism is the alteration of the endometrium (womb lining). The hormonal environment created by Marvelon makes the endometrium less receptive, which reduces the likelihood of implantation.

While this mechanism is considered a secondary contributor to contraceptive efficacy, it provides a further layer of protection.

Clinical evidence and UK prescribing guidance

Combined oral contraceptives have been extensively studied over more than 60 years and are among the most thoroughly evaluated medicines in clinical use.

The efficacy of Marvelon in preventing pregnancy has been demonstrated in multiple clinical trials, with a Pearl Index (the number of pregnancies per 100 woman-years of use) of approximately 0.1 to 0.5 with perfect use and around 9 with typical use (accounting for missed pills and other errors).

The Faculty of Sexual and Reproductive Healthcare (FSRH) of the Royal College of Obstetricians and Gynaecologists provides UK clinical guidelines on contraception.

The FSRH guideline on combined hormonal contraception (updated 2019) states that all combined oral contraceptives are highly effective when used correctly.

The guideline notes that COCs containing levonorgestrel or norethisterone with 30 micrograms ethinylestradiol carry the lowest VTE risk and should be considered first-line.

However, COCs containing desogestrel (such as Marvelon) remain appropriate for women who prefer them or who experience side effects on second-generation pills, provided VTE risk has been assessed.

NICE guidance on contraception recommends offering women a choice of methods, with counselling about the comparative risks and benefits of each.

The decision to prescribe a particular COC should be shared between the prescriber and the woman, taking into account individual preferences and risk factors.

Marvelon compared with other combined pills

The UK market offers a wide range of combined oral contraceptives, and understanding the differences helps put Marvelon in context.

Microgynon 30 and Rigevidon contain levonorgestrel 150 micrograms and ethinylestradiol 30 micrograms; they are second-generation pills with the lowest VTE risk and are the most commonly prescribed COCs in the UK.

Mercilon contains the same progestogen as Marvelon (desogestrel) but with a lower oestrogen dose (20 micrograms ethinylestradiol), which may suit women who experience oestrogen-related side effects such as headaches, breast tenderness, or nausea, though very low oestrogen doses may be associated with more breakthrough bleeding.

Yasmin contains drospirenone (a progestogen with anti-androgenic and mild anti-mineralocorticoid properties) and ethinylestradiol 30 micrograms.

It may be preferred for women with acne or fluid retention but carries a VTE risk similar to third-generation pills.

Qlaira and Zoely contain natural oestradiol rather than ethinylestradiol and are sometimes described as "newer generation" pills with potentially fewer metabolic effects, though their VTE risk profile is still being established.

The progestogen-only pill (POP), such as Cerazette (desogestrel 75 micrograms), is an alternative for women who cannot or prefer not to take oestrogen.

Long-acting reversible contraceptives (LARCs), including the intrauterine system (Mirena), implant (Nexplanon), and injectable (Depo-Provera), offer higher effectiveness with less reliance on daily adherence and are recommended by NICE as first-line options where appropriate.

Dosage and administration

Take one Marvelon tablet at the same time each day for 21 days. Swallow the tablet whole with water.

Each tablet in the strip is marked with a day of the week to help you keep track. After taking all 21 tablets, stop for 7 days.

During this hormone-free interval, the fall in hormone levels triggers a withdrawal bleed that resembles a period.

Start the next 21-day strip on day 8, regardless of whether bleeding has finished.

It is important to take the pill at a consistent time each day.

Setting a daily alarm or linking the pill to a routine activity (such as brushing your teeth) can help.

If you start Marvelon on the first day of your period, contraceptive protection begins immediately.

If you start at any other time in your cycle (a "Quick Start"), you should use additional barrier contraception (condoms) for the first 7 days.

Missed pill guidance follows FSRH recommendations.

If one pill is missed (taken more than 24 hours but fewer than 48 hours late), take it as soon as you remember and continue the pack.

No additional contraception is needed.

If two or more pills are missed (48 hours or more late), take the most recently missed pill, discard any earlier missed pills, and continue the pack.

Use condoms for the next 7 days.

If there are fewer than 7 active pills remaining in the pack, omit the pill-free interval and start the next pack immediately.

Tailored regimens: running packs together

Traditionally, COCs have been taken in a 21/7 pattern (21 active pills, 7-day break). However, there is no medical need for a monthly withdrawal bleed.

The FSRH supports flexible and extended regimens, which can reduce headaches, mood changes, period pain, and other symptoms that occur during the hormone-free interval.

Options include continuous use (running packs together indefinitely, with a 4-day break if breakthrough bleeding occurs for 3 to 4 consecutive days), a 63/4 regimen (63 active pills followed by a 4-day break), or a 21/4 regimen (shortening the break to 4 days instead of 7).

Discuss these options with your prescriber or pharmacist.

Side effects of Marvelon

Common side effects

Headache, breast tenderness, mood changes (including low mood and irritability), nausea, and breakthrough bleeding or spotting are the most commonly reported side effects.

Breakthrough bleeding is more likely during the first 2 to 3 cycles and usually resolves with continued use. If it persists beyond 3 months, consult your prescriber.

Other common effects include bloating, mild weight fluctuation, and changes in libido.

Venous thromboembolism

The most clinically significant risk associated with combined oral contraceptives is venous thromboembolism (VTE), which encompasses deep vein thrombosis (DVT) and pulmonary embolism (PE).

The background incidence of VTE in women of reproductive age who are not taking hormonal contraception and are not pregnant is approximately 2 per 10,000 per year.

The incidence among users of COCs containing levonorgestrel is approximately 5 to 7 per 10,000 per year.

For COCs containing desogestrel, the incidence is estimated at 9 to 12 per 10,000 per year.

The risk is highest in the first year of use and after restarting following a break of 4 weeks or more.

Symptoms of DVT include sudden swelling, pain, warmth, and redness in one leg, typically the calf.

Symptoms of PE include sudden breathlessness, sharp chest pain (worse on breathing in), and coughing up blood. These are medical emergencies.

Call 999 immediately if you experience these symptoms.

Arterial thromboembolism

Arterial events such as myocardial infarction and ischaemic stroke are rare in young women but are associated with COC use, particularly in the presence of additional risk factors: smoking (especially over age 35), hypertension, migraine with aura, diabetes with vascular complications, and severe hyperlipidaemia.

The FSRH recommends that COCs should not be prescribed to women with migraine with aura at any age, as the combination substantially increases the risk of ischaemic stroke.

Other important side effects

Elevated blood pressure may occur during COC use and should be checked annually. Liver tumours (hepatocellular adenoma) are a very rare association. Gallbladder disease risk is slightly increased.

The relationship between COC use and breast cancer has been extensively studied; current evidence suggests a very small increased risk during use that disappears within 10 years of stopping.

Long-term COC use (5 or more years) is associated with a small increased risk of cervical cancer, which declines after discontinuation.

When to seek urgent medical advice

Stop taking Marvelon and seek urgent medical help if you develop sudden severe headache, visual disturbance, sudden leg pain or swelling, chest pain, breathlessness, or signs of a stroke (facial drooping, arm weakness, speech difficulty).

Call 999 in an emergency.

Contact your GP or call NHS 111 if you experience persistent mood changes, new onset migraine, sustained blood pressure elevation, or persistent breakthrough bleeding.

Report suspected adverse reactions to the MHRA at yellowcard.mhra.gov.uk .

Warnings and precautions

Contraindications

Marvelon must not be used in women with a current or past history of VTE or arterial thromboembolism, known thrombophilic disorders, uncontrolled hypertension, migraine with aura, diabetes with vascular complications, severe hepatic disease or liver tumours, pancreatitis associated with severe hypertriglyceridaemia, known or suspected sex-steroid-dependent malignancies, undiagnosed vaginal bleeding, or hypersensitivity to any component.

Risk assessment before prescribing

Your prescriber should assess blood pressure, BMI, smoking status, personal and family history of VTE, cardiovascular history, migraine history, and any current medications before initiating Marvelon.

The UK Medical Eligibility Criteria (UKMEC) for contraceptive use, published by the FSRH, categorises conditions according to suitability for combined hormonal contraception.

Category 3 (risks generally outweigh benefits) and Category 4 (unacceptable health risk) conditions are contraindications. Assessment should be repeated annually.

Surgery and immobility

If you are due to have major surgery with prolonged immobilisation, your prescriber may advise stopping Marvelon 4 to 6 weeks before the procedure and restarting once you are fully mobile.

Short periods of immobility, such as long-haul flights, may increase VTE risk; staying hydrated, wearing compression stockings, and moving regularly can help reduce this risk.

Drug interactions

Enzyme-inducing medicines reduce the effectiveness of combined oral contraceptives by increasing the hepatic metabolism of ethinylestradiol and desogestrel.

These include rifampicin, rifabutin, carbamazepine, oxcarbazepine, phenytoin, phenobarbital, primidone, topiramate (at doses above 200 mg daily), certain antiretrovirals, and St John's wort.

If a short course (2 months or less) of an enzyme-inducing drug is needed, additional contraceptive precautions and adjustment of the pill-free interval are required.

For long-term enzyme-inducing medication, an alternative contraceptive method should be used.

Pregnancy and breastfeeding

Marvelon must not be taken during pregnancy. If you become pregnant while taking the pill, stop immediately.

There is no evidence that accidental exposure to COCs during early pregnancy causes harm to the baby.

Combined oral contraceptives are not recommended during breastfeeding in the first 6 weeks postpartum, as they may reduce breast milk production.

The FSRH advises that COCs can be started from 6 weeks postpartum if the woman is not fully breastfeeding.

How to get Marvelon in the UK

Marvelon is a prescription-only medicine available through the NHS.

You can obtain a prescription from your GP, a sexual health or family planning clinic, or an authorised online prescriber registered with the General Pharmaceutical Council (GPhC).

Contraception, including the pill, is free on the NHS throughout the United Kingdom, including England, Scotland, Wales, and Northern Ireland.

If you obtain Marvelon through a standard NHS prescription (rather than a contraceptive clinic), the usual prescription charge of 9.90 pounds applies in England; prescriptions are free in Scotland, Wales, and Northern Ireland.

Lifestyle advice while taking Marvelon

Combined oral contraceptives do not require specific dietary restrictions, but maintaining a healthy lifestyle supports overall cardiovascular health and may reduce the risk of rare side effects.

If you smoke, stopping is strongly recommended, as smoking substantially increases cardiovascular risk.

Limit alcohol to no more than 14 units per week, spread across 3 or more days. Stay physically active and maintain a healthy weight.

Attend regular cervical screening (smear tests) as invited by the NHS Cervical Screening Programme. Be breast-aware and report any changes to your GP.

Sources

• Marvelon Tablets, Summary of Product Characteristics (EMC)
• Desogestrel with ethinylestradiol, British National Formulary (BNF)
• FSRH Clinical Guideline: Combined Hormonal Contraception
• Combined pill, NHS
• MHRA Yellow Card Scheme